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Abstract
Patients with multiple sclerosis (MS) have multiple causes of poor sleep and potential
triggers may relate to MS-related symptoms, co-morbidities and adverse effects from
medication. Sleep disorders may occur independently of demographic factors, gender
and clinical condition. The real frequency of sleep disturbances in MS and their impact on
the patients’ quality of life are unknown. The prevalence of sleep problems in the popula-
tion with MS ranges between 47 and 62% and is more frequent in women, as well as
having a higher risk of mortality. High psychological burden has been associated with
poor sleep and with increased risk of co-morbid conditions such as heart disease, obesity,
dyslipidemia and diabetes, which may have a profound impact on long-term health. The
poor sleeping patients with MS were more likely to report fatigue and sleepiness. Insom-
nia is present in mood disorders, restless leg syndrome (RLS), pain, nocturia and obstruc-
tive sleep apnea (OSA), in patients with MS. All the symptoms are intermixed, and it is not
possible to discern the precipitating factor or the perpetuating factor. Clinicians should
routinely ask about sleep when forming a comprehensive care plan for patients with MS.
Sleep specialty referrals should be considered for management of conditions that require
polysomnography (PSG) diagnosis.
Keywords: sleep disorders, insomnia, sleepiness, fatigue, respiratory disorders during
sleep, cognitive impairment, cognitive behavioral therapy, multiple sclerosis
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that is
increasingly prevalent in young adults. Patients with MS have multiple causes of poor sleep,
and potential triggers may be related to MS-related symptoms, co-morbidities and adverse
effects from drug therapy.
Major sleep disorders have been reported to be associated with numerous co-morbid condi-
tions, including heart disease, obesity, stroke and diabetes [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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The poor sleepers among patients with MS are more likely to report fatigue (one of the
most frequent symptoms in MS) and pain (a co-morbid condition to MS-related fatigue but
is confounded by depression and medication for treating pain or pain-induced sleep disor-
der) [1].
All the symptoms are intermixed, and it is not possible to discern the precipitating factor
and the perpetuating factor. In this respect, sleepiness and fatigue may converge in some
situations [1].
Insomnia is present in mood disorders (depression and anxiety), restless leg syndrome (RLS),
pain, nocturia and others [1]. RLS is also an important cause of pain in patients with MS. Sleep
disorders may occur independently of demographic factors such as gender and clinical-
demographic factors. High psychological burden has been said to be independently associated
with poor sleep patients with increased risk of co-morbid conditions such as heart disease,
obesity and diabetes, which may have a profound impact on long-term health. The reverse
situation is also possible.
The frequency of sleep disturbances in MS and their impact on the patients’ quality of life are
unknown. The prevalence of sleep problems in the MS population ranges from 47 to 62%, with
a higher prevalence in women [2–5]. Sex hormones and genetic mechanisms, psychosocial
factors, certain physical factors that disrupt sleep, such as pain or bladder dysfunction may
contribute to sleep differences between women and men [5].
Obstructive sleep apnea (OSA), RLS and chronic insomnia in particular are frequent problems
in the MS population, and play a key role in the development of debilitating fatigue and other
poor functional outcomes in MS. Yet, despite their impact, sleep disorders in MS remain
critically under-recognized in most clinical settings. A recommended approach to the fatigued
patient with MS is also highlighted [6].
Sleep disorders during the course of MS may be secondary to numerous symptoms arising
from the disease itself or can be primary with a common biological link. In either of the two
cases, a bidirectional relationship exists between these co-morbid conditions [7].
Sleep disturbances have been associated with increased risk of mortality, cardiac disease,
obesity and diabetes [8] and can contribute to the depression, pain and fatigue symptoms that
are commonly seen in MS patients, which are often disabling [3, 9].
Sleep disorders are under-recognized in persons with MS. These sleep disorders can contribute
significantly to fatigue, other daytime dysfunction and poor quality of life. A systematic, practi-
cal approach that takes into account clinical features of MS is recommended to enhance recogni-
tion of these conditions and facilitate appropriate treatment. Clinicians caring for patients with
MS should routinely screen for sleep disturbances and initiate diagnostic workups, if clinically
indicated.
Sleep specialty referrals should be considered for management of conditions that require
polysomnography (PSG) diagnosis, for complex patients who present a diagnostic challenge
and for patients who do not respond to first-line treatments. Clinicians should also routinely
ask about sleep when forming a comprehensive care plan for patients with MS.
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2. Effect or influence of multiple sclerosis in sleep disorders
2.1. Insomnia
Sleeplessness or insomnia is an inability to fall asleep or to stay asleep as long as desired.
Insomnia is described as a complaint of prolonged sleep-onset latency, disturbance of sleep
maintenance or the experience of non-refreshing sleep [10]. Episodic insomnia can usually be
traced to an acute psychological stressor or an environmental change. Chronic insomnia may
be related to a combination of factors including depression, poor sleep hygiene, learned
sleeplessness, sleep-disordered breathing, nocturia, drugs or extrinsic factors such as noise [6,
11].
Patients with MS face a high risk of insomnia of around 40% [6] compared to roughly 10–15% in
the general population [12]. Awakening too early in the morning is the most common symptom
(58%) [13].
Primary symptoms of MS that can condition the onset of insomnia are neurogenic bladder
(nocturia), spasticity, sexual dysfunction, neuropathic pain, paroxysmal phenomena, depres-
sion and anxiety [7].
Insomnia affects daytime activities, because of fatigue, mood disturbances (depression and
anxiety), attention, concentration and memory impairment [7]. Higher fatigue scores have also
been found to correlate with insomnia, especially middle insomnia [13].
2.1.1. Diagnostic approach
Patients with insomnia may complain of difficulty falling asleep, difficulty staying asleep or
waking up sooner than desired [10]. There are screening tools to identify such patients.
The Pittsburgh Sleep Quality Index (PSQI) measures seven domains: subjective sleep quality,
latency, duration, habitual efficiency, disturbances, use of sleep medication and daytime dys-
function over the last month. Each of these seven domains is self-rated by the individuals. The
score of each question is based on a scale from 0 to 3, in which a score of 3 demonstrates the
negative extreme on the Likert Scale. A global sum of 5 or greater indicates a poor sleeper
(sensitivity of almost 100% for insomnia) [14, 15].
Insomnia Severity Index (ISI): a seven item questionnaire designed to assess the nature,
severity, and impact of insomnia in adults. Scores >15 reflect moderate clinical insomnia. It is
also a useful tool to monitor the effects of insomnia interventions [6].
Athens Insomnia Scale (AIS): a psychometric instrument designed for quantifying sleep diffi-
culty. It consists of eight items: the first five pertain to sleep induction, awakenings during the
night, final awakening, total sleep duration and sleep quality; while the last three refer to well-
being, functioning capacity and sleepiness during the day. Either the entire eight-item scale
(AIS-8) or the brief five-item version (AIS-5), which contains only the first five items, can be
used. The score of each question is based on a scale from 0 to 3, where a score of 3 indicates the
negative or normal extreme on the Likert Scale. A cut-off score of ≥6 on the AIS is used to
establish the diagnosis of insomnia [16].




After detecting insomnia, amelioration of any precipitating causes of insomnia is a cardinal step
in its management. Medications or substances that may contribute to insomnia should be
reduced or discontinued, if possible, there should be a check on which drugs the patient is taking
(medications used to alleviate MS-related symptoms, including over-the-counter medications).
Selective serotonin reuptake inhibitors, while helpful for depressive symptoms, may worsen
insomnia.
Stimulants and wake-promoting agents, which are commonly used for fatigue, may interfere
with sleep initiation if taken during the late afternoon or early evening hours.
Antihistamines, which are used as sleep aids by up to 25% of patients with MS, have the
potential to worsen RLS, and thereby worsen sleep-onset insomnia [6].
Co-morbid symptoms must be identified and treated: neuropathic pain (tricyclic antidepres-
sants and the α-2-δ ligand pregabalin), spasticity (baclofen or tizanidine) and urinary urgency
(anticholinergics) [6].
Cognitive behavioral therapy (CBT) is an innovative psychotherapy approach. CBT treatment
could reduce anxiety and depression by changing thoughts and beliefs and consequently
reduce the symptoms of insomnia [6, 17].
Pharmacological therapies can be considered if more conservative strategies have been exhausted
or are not fully effective: benzodiazepines, benzodiazepine agonists, melatonin receptor agonists
and orexin receptor antagonists.
2.2. Hypersomnia
Excessive daytime sleepiness (EDS)/excessive daytime drowsiness disrupt daily performance.
Hypersomnia may be due to acute thalamus injuries, mental disorders, especially depressive
symptoms, sleep deprivation or as a consequence of received treatments.
2.2.1. Diagnostic approach
The Epworth Sleepiness Scale (ESS) is a screening tool that assesses sleepiness and has eight
items. ESS values equal to or greater than 10 indicate excessive daytime sleepiness (EDS), and
in this case, patients should undergo polygraphy or PSG (screening for sleep apnea) [18].
All fatigued patients should be asked about sleepiness and fill in the Epworth Sleepiness Scale
(ESS) as these are not always associated with sleepiness.
Magnetic resonance imaging (MRI) should be performed because of the need to identify
structural lesions in the brain.
2.2.2. Management
After detecting hypersomnia, the physician should check for any medications involved and
withdraw them if possible, treat acute lesions of multiple sclerosis with corticosteroids,
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indicate adequate sleep hygiene and assess whether specific treatment is needed to improve
daily performance.
2.3. Restless leg syndrome
The four main criteria for diagnosis of RLS are: (1) unpleasant sensations in the legs; (2)
worsening of the symptoms during rest; (3) relief of the symptoms by movement and (4)
exacerbation of the symptoms in the evening or at night [19].
The periodic limb movement disorder (PLMD) includes repetitive periodic shaking episodes
lasting between 0.5 and 5 seconds that occur during sleep every 20–40 seconds; mainly in the
legs, but sometimes in the arms.
RLS and PLMD aremotor disorders of sleep considered separate clinical entities, both conditions
have the potential to cause disrupted sleep, share similar pathogenesis and have an increased
prevalence among persons with MS. PLMD also frequently occur in the absence of RLS.
Most RLS patients (80–90%) have periodic leg movements PLM during sleep. They can cause
arousals or micro-arousals leading to non-refreshing sleep, daytime sleepiness and fatigue.
The prevalence of RLS in the general population ranges from 1 to 12% [20]. The prevalence of
RLS in MS patients is two to five times higher than in the general population [21–24].
Differentiating RLS from other sensory and motor symptoms of MS can be difficult, as MS
patients frequently suffer from spasms, dysesthesia, paraesthesia and spasticity in the legs,
which worsen with immobility [25].
Predictive factors for RLS in MS patients include: older age, longer disease duration, progres-
sive primary forms, greater disability as measured by the Expanded Disability Status Scale
(EDSS), especially in the pyramidal and sensory subscales and shaking of the legs before onset
of sleep [26]. Furthermore, RLS symptoms are more severe when associated with MS than
when not associated with MS.
MS patients with RLS have more cervical cord lesions than those patients without RLS. These
lesions possibly disrupt the ascending and descending pathways with cerebrospinal discon-
nection leading to these symptoms [10].
Primary RLS is a genetic form of RLS with autosomal dominant transmission [27]. Four genes
have been associated with this syndrome [28] but no crossing over of those involved in MS
[10].
Pathogenesis of RLS and PRLS shows dysfunction of downstream dopaminergic pathways,
namely diencephalospinal and reticulospinal pathways, that project to the spinal cord. These
pathways, via dopaminergic transmission, are responsible for the suppression of sensory
inputs and motor excitability, and are susceptible to damage from diseases affecting the spinal
cord. Impaired iron metabolism is also thought to contribute to the pathogenesis of RLS, as
iron is a cofactor for a rate-limiting step in the synthesis of dopamine [6, 10].
Certain medications used in the management of persons with MS, such as antiemetic drugs,
antipsychotic dopamine antagonists, antidepressants and antihistamines can also cause or
worsen RLS [6, 10].




Many descriptors can be used by patients to describe the restless sensation, including creeping,
crawling, itching, burning, tightening, tingling or pain.
Symptoms of leg tightness relieved by voluntary movement suggest RLS, whereas involuntary
spasms, even if a circadian component is endorsed, suggest spasticity. Rhythmic involuntary
movements triggered by stretching or certain leg positions suggest clonus.
The Restless Legs Syndrome Diagnostic Index (RLS-DI) is a 10-item questionnaire. Scores
range from 22 (no RLS) to +20 (definite RLS). A score of +11 yields 93.0% sensitivity and
96.1% specificity to accurately diagnose RLS [6].
Diagnosis of PLMD requires overnight PSG to assess for the presence of leg movements [6, 10].
The RLS Rating Scale is a useful tool to track treatment response and is a 10-item self-administered
scale. Scores of 11–20 reflect moderate RLS.
2.3.2. Management
Iron supplementation should be implemented for a ferritin level of less than 50 ng/ml.
Reduction or discontinuation of medications and substances that can cause or worsen RLS or
PLMD (dopamine antagonists, lithium, selective serotonin reuptake inhibitors, serotonin-
norepinephrine reuptake inhibitors, antihistamines, tricyclic antidepressants, alcohol, tobacco
and caffeine) is recommended.
Dopamine agonists (pramipexole, ropinirole and rotigotine), and the α-2-δ ligand gabapentin
and anticonvulsants are first-line treatments.
Benzodiazepines and opioid agents (oxycodone and methadone) are second line treatments.
Treatment for refractory RLS, or augmentation in response to dopaminergic therapy, is also
likely to be optimized by sleep specialty care [6].
2.4. Respiratory disorders during sleep
Sleep-disordered breathing is characterized by episodes of nocturnal hypopnea and apnea
resulting in a reduction or a cessation of airflow in the upper airway.
Patients with sleep-disordered breathing may complain of “fatigue,” decreased concentration,
mood changes, erectile dysfunction, nocturia and mood changes, all these complaints are
similar to those experienced in MS [29].
2.4.1. Apnea and hypopnea
Apneas and hypopneas may be caused by a collapse of the tissues and muscles in the pharynx
(obstructive apnea/hypopnea) or a failure in the medullary respiratory signal (central apnea/
hypopnea) [10].
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Maintenance of upper airway patency during sleep requires an increase in pharyngeal tone
that is primarily mediated by efferent motor output from cranial nerves X and XII to the palatal
and genioglossus muscles, respectively. This process is largely influenced by afferent sensory
input from pressure receptors in the upper airway, peripheral chemoreceptors in the aortic and
carotid bodies, and brainstem respiratory generators. Pathophysiological processes that dis-
rupt these tightly regulated brainstem pathways have the potential to impair nocturnal respi-
ration. The medullary reticular formation is responsible for controlling automatic breathing
during sleep [10].
Causative factors include obesity, craniofacial abnormalities, enlarged tonsils, congestive heart
disease and degenerative central nervous system (CNS) disorders, to name a few [10].
Such apnea and hypopnea episodes may lead to nocturnal hypoxemia, frequent awakenings and
daytime somnolence. When the apneas are associated with respiratory effort, the term obstruc-
tive apnea is used, and central apnea is used when there is a lack of respiratory effort [10].
Central sleep apnea is diagnosed when more of 50% of the events are central in patients with
both central and obstructive apneas.
2.4.2. Obstructive sleep apnea
Obstructive sleep apnea is characterized by repeated episodes of upper airway obstruction and
hypoxia during sleep [6].
The incidence of OSA in patients with MS is 2–21% and is one of the most common respiratory
disorders [10].
Patients with MS who have a diagnosis of OSA and those at an elevated risk of OSA have
increased fatigue and diminished quality life comparedwith undiagnosed or low-risk patients [6].
Sleepiness is primarily a result of acutely or chronically reduced sleep time, or poor sleep
quality. Apnea severity may correlate with impaired cognition in MS [6].
2.4.2.1. Diagnostic approach
Questions must be asked about symptoms of snoring, pauses in breathing witnessed by a
bed partner, gasping or choking upon awakening, non-restorative sleep, excessive daytime
hypersomnolence or fatigue, cognitive disturbances and nighttime awakenings, any of
which may arise in part from underlying OSA [6].
Dysarthria or dysphagia, obesity, increased neck circumference, crowded oropharyngeal inlet,
retrognathia, or micrognathia are common physical exam findings [6].
The STOP-Bang questionnaire is a screening tool consisting of eight questions and measures
that form the acronym snoring, tired, observed apnea, Blood Pressure-Body Mass Index, age,
neck circumference and gender. Scores of 3 or higher indicate an elevated risk of OSA [6].
A full-night PSG is necessary to demonstrate the presence of obstructive respiratory events
during sleep to confirm the diagnosis of OSA. These events may be partial (hypopneas) or
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complete (apneas), but must demonstrate evidence of a reduction in airflow during sleep,
despite continued effort to breathe [6].
2.4.2.2. Management
Management strategies for sleep-disordered breathing should take into account the patient’s
primary apnea subtype, apnea severity, co-morbidities and behaviors, and other MS-specific
symptoms or limitations. Guidance by a sleep medicine physician is often helpful [6]. Discon-
tinuation of medication, such as opiates, antispasmodics or CNS depressants medications [6].
Positive airway pressure (PAP) therapy is delivered by a mechanical device and mask to splint
the upper airway open during sleep. Supplemental oxygen, bi-level PAP and adaptive servo
ventilation are other improvements that these devices have [6].
Oral appliances work by repositioning the mandible in the anterior and inferior position [6]. By
improving nocturnal oxygen saturation and sleep quality, PAP therapy effectively reduces
fatigue and can be effective in the treatment of depression. This is especially important given
the link between fatigue and depression in MS [6, 18].
Disease-modifying therapy use, in particular emerged as a strong predictor of reduced apnea
severity, raising interesting possibilities about the role of local and/or systemic inflammation in
OSA [6].
2.4.3. Central sleep apnea
Central sleep apnea (CSA) is rare, and the prevalence is unclear in the general population. CSA
involves repeated complete or partial reduction of airflow, caused by an intermittent lack of
respiratory effort by failure in the medullary respiratory signal [10].
While the prevalence of CSA is less than that of OSA, patients with CNS disorders that affect
pontine and medullary respiratory generators, including MS, may be at increased risk for this
condition as well even nocturnal death (Ondine’s curse) [6, 10].
CNS and brain stem-related nocturnal respiratory abnormalities such as central sleep apnea,
paroxysmal hyperventilation, hypoventilation, respiratory muscle weakness and respira-
tory arrest have all been described and should be considered in this patient population in
the evaluation of symptoms of daytime somnolence, increased fatigue and non-refreshing
sleep [11].
2.4.3.1. Diagnostic approach
In patients with symptoms of daytime somnolence, increased fatigue and non-refreshing sleep,
the physician must ask about nocturnal respiratory abnormalities [11] and look for evidence of
reduction in airflow in the absence of respiratory effort in an overnight PSG.
In patients with both central and obstructive apneas, central sleep apnea is diagnosed when
more than 50% of the events are central. The coexistence of OSA or CSA and MS has been
described by several authors [2, 10, 30].
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2.4.3.2. Management
In the cases of central sleep apnea not symptomatic or central sleep apnea during sleep-
wake transition (20% of central sleep apnea cases resolve spontaneously) observation is
recommended.
In other cases, PAP treatment, adaptive servo ventilation, oxygen, added dead space, carbon
dioxide inhalation and overdrive atrial pacing are needed.
2.4.4. Nocturnal urinary disorders
Sleep disturbance is associated with outcomes such as increased risk of falls and mortality.
Nocturia may both precipitate poor sleep and perpetuate insomnia (awakenings associated
with nocturia may themselves be perpetuating factors) [31].
Overactive bladder (OAB) syndrome is a condition that accompanies urgency (a significant
factor for sleep disruption), with or without incontinence, frequently with increased daytime
frequency and nocturia [32]).
Nocturia is defined by the International Continence Society as the complaint that an individual
has to wake at night one or more times to void. It reflects the relationship between the amount
of urine produced while asleep, and the storage by the bladder of urine received. Nocturia is a
symptom rather than a disease and causative categories have been proposed and is the most
common storage symptom in the general population [32].
Nocturia can occur as part of lower urinary tract dysfunction (LUTD), notably in overactive
bladder syndrome (OAB). Nocturia can also occur in association with other forms of LUTD,
such as bladder outlet obstruction or chronic pelvic pain syndrome [33].
Nocturia is due to nocturnal polyuria, a decreased nocturnal bladder capacity or a mixture of the
two. Various duplicating factors for nocturia have been reported, including pathological conditions
such as diabetes, LUTD, cardiovascular disease, primary sleep disorders and sleep apnea [32].
Nocturia is a feature of systemic conditions affecting water and salt balance, leading to excessive
production of urine at all times (global polyuria) or primarily at night (nocturnal polyuria), so
that nocturia can be a systemic symptom such as cardiovascular, endocrine and renal disease can
affect water and salt homeostasis, leading to an increased rate of urine production [33].
Nocturia can significantly influence quality of life, efficiency, vigor and awareness of health,
primarily due to sleep disruption.
2.4.4.1. Diagnostic approach
Asking how many times the patient wakes up at night because of nocturia, whether urinary
urgency exists and the characteristics of urination, quantity of fluid intakes, physical exercise,
medication being taken, etc. is also necessary for the diagnosis of urinary problems.
The use of specific questionnaires such as the PSQ, ISI and ASI for the diagnosis of insomnia or
the ESS for the diurnal hypersomnia helps the physician to approach the functional repercus-
sion of the problem.
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The study occasionally needs to be completed with ultrasound studies, urodynamics, MRI and
urinary sediment to identify LUTD or OAB problems.
2.4.4.2. Management
Interventions targeting nocturia may potentially improve sleep quality [31].
Hygienic measures such as reduced fluid intake at the end of the evening and frequently going
to the bathroom during the day can help. Adequate treatment of co-morbid conditions such as
diabetes mellitus, congestive heart failure or sleep apnea requires direct intervention for
improvement nocturia.
Anticholinergics, mirabegron, a-blockers, 5-a reductase inhibitors, oral phosphodiester-ase-5
inhibitors, desmopressin, diuretics, sleep-promoting agents and phytotherapy are used to treat
urinary problems [33]. Half of MS patients with moderate to severe overactive bladder symp-
toms are treated with an anticholinergic medication [18].
Antimuscarinic drugs (Solifenacin), the most appropriate treatment for OAB, inhibited bladder
stimulation may originate a decrease of drive to the brain stem, improve urination urgency
and frequency and effectively reduce involuntary contractions and increase bladder capacity
in patients with storage symptoms. The night time dosing of antimuscarinic drugs may
improve tolerance compared to daytime dosing [32].
Antidiuretic therapy using clinician-directed dose titration has been reported to be more
effective than placebo in terms of reduced nocturnal voiding frequency and duration of
undisturbed sleep [33].
Nocturia severity improvement contributes to overall improvements in health-related quality
of life [33].
The impact of treatment for nocturia in MS fatigue is unknown [18]. Non-pharmacological
therapies such as cognitive behavioral therapy for nocturia (CBT-N) act on the abovementioned
perpetuating factors. Sleep restriction entails reducing the excessive time in bed (a common
occurrence in insomnia) and thereby improves sleep efficiency.
3. Effect of the quality of sleep in multiple sclerosis
Sleep disturbances have been associated with increased risk of mortality, cardiac disease,
obesity and diabetes [8] and can contribute to the depression, pain and fatigue symptoms that
are commonly seen in MS patients, which are often disabling [3, 9, 10].
3.1. Fatigue
Fatigue is defined as a subjective lack of physical or mental energy perceived by the patients or
their caregivers which interferes with desired activities of daily living and it is the most
frequent symptom in MS [18].
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Between 80 and 97% [6] of patients report chronic fatigue, and more than 33% of patients rate
this symptom as the most disabling [34–36].
Fatigue may occur at any stage of the disease and can even precede MS onset by several years.
Fatigue affects the social and professional capabilities of patients, is a major reason for early
retirement, reduced employment and is considered to be one of the main causes of impaired
quality of life among MS patients, regardless of depression or disability [18].
Fatigue starts early in the morning and increases during the day. The perception of fatigue is
exacerbated with environmental temperature and humidity [25], with age, [36] greater EDSS,
mental or physical activity, infections and food ingestion [37].
Fatigue also deteriorates cognitive domains, such as information processing, memory and atten-
tion, [35] and it has significant socioeconomic consequences, including loss of work hours and in
some instances, loss of employment, as well as family relationships and leisure time [36].
Fatigue is a symptom in MS patients and may have multi-factorial causes such as immunologic
abnormalities (pro-inflammatory cytokines such as INF-α), endocrine influences (cortisol and
dehydroepiandrosterone (DHEA)), axonal loss, altered patterns of cerebral activation, sleep
disorders (RLS, chronic insomnia, sleep-disordered breathing and altered sleep microstruc-
ture), depression and medications used to treat MS symptoms or immunomodulatory and
immunosuppressive treatments [7, 38, 39].
“Primary” fatigue is related to the pathological changes of the disease itself, and results from a
spectrum where one pole is the inability to generate the force required to perform the task due
to a failure of force production at the muscle level “peripheral fatigue”; and the other pole is the
inability to sustain the required neural drive to muscle because of supraspinal, spinal and even
peripheral nerve contribution “central fatigue.”
“Central fatigue” can be the result of both cognitive and physical exertion and can reflect either
a subjective sensation (fatigue) or an objective change in performance (fatigability) [37]. Dopa-
mine imbalance plays a major role in developing fatigue. Central fatigue is a failure of the non-
motor functions of the basal ganglia.
The subjective feeling of fatigue is related to inflammation and increased levels of cytokines
such as interleukin-1 (IL-1), IL-6 and TNF-alpha [40].
“Secondary” fatigue attributed to mimicking symptoms, co-morbid sleep, irritable bowel
syndrome, migraine, mood disorders, depression and anxiety and medication side effects [36,
37]. Persons with secondary fatigue report greater levels of fatigue than those with isolated
primary fatigue [36].
There is a great variability in MS lesions from extensive areas of destruction during MS attacks,
healing processes of and neuroplasticity. The clinical manifestations of fatigue do not seem to
exclusively depend on the structural damage, but rather on the balance between restorative
and inflammatory/degenerative processes and the rupture of the neural network [37].
In this respect, there is evidence that supports these hypotheses, linking fatigue with structural
or functional abnormalities (atrophy in the thalamus, corpus callosum, cortical gray matter
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regions: superior frontal and inferior parietal gyrus, parietal lobe) within various brain net-
works (the cortico-subcortical circuit as a substrate for MS fatigue and the involvement of a
“fronto-striatal network”), greater activation of the premotor area ipsilateral to the movement
with functional MRI (fMRI), decreased N-acetylaspartate-creatine ratio (NAA/Cr) as a marker
of axonal dysfunction. Resting-state fMRI studies show changes in functional connectivity (FC)
of the basal ganglia including reward processing and motivation. In addition to motor func-
tions, the abovementioned aspects are involved in the pathophysiology of fatigue [18].
3.1.1. Diagnostic approach
Patients with MS report being fatigued very often, sometimes it is just the feeling of lack of
energy but in others it interferes with their work or their daily life. There are tools that help
quantify the degree of fatigue which are described below.
Severity Scale (FSS): is a self-administered questionnaire with nine items (questions) investi-
gating the severity of fatigue in different situations during the previous week. Grading of each
item ranges from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement and the
final score represents the mean value of the 9 items. A total score of less than 36 suggests that
you may not be suffering from fatigue [24].
Modified Fatigue Impact Scale (MFIS): The full-length MFIS consists of 21 items (total score 0–
84, 38 as a cutoff to discriminate fatigued from non-fatigued individuals) while the abbreviated
version has 5 items (0–20.). The abbreviated version can be used if time is limited but the full-
length version has the advantage of generating physical, cognitive and psychosocial function-
ing subscales. The MFIS is one of the components of the MS quality life inventory [37].
MS patients, regardless of their fatigue level, have a significantly high frequency of RLS, higher
Epworth sleepiness scale (ESS) scores, and higher PSQI scores. The time in bed, wake time
after sleep onset %, total arousal index, limb movement arousal index and periodic limb
movement arousal index are abnormal. The sleep efficiency index and sleep continuity index
are lower in fatigued MS patients than non-fatigued MS patients. The PSQI results also suggest
more disrupted sleep in fatigued MS patients. For all of the reasons above, quality of sleep
studies should be performed with fatigued MS patients.
Once the patient has been identified with fatigue, it is necessary to investigate whether other
co-morbidities are present (depression, anxiety, sleep disturbance, diabetes, heart disease,
obesity, anemia, thyroid disease and nocturnal urinary disorders), what factors influence
perpetuating fatigue and what situations can be modified in their lifestyle [6].
3.1.2. Management
Interventions targeting fatigue may potentially improve sleep quality and quality of life [31].
Pharmacological interventions are also reviewed and if there is evidence that a drug is involved
in fatigue, it should be suppressed or the dose decreased [18]. Disease-modifying treatments
(DMTs) are generally used to reduce relapses and progression and they occasionally cause an
increase in fatigue, and in these circumstances it is important to change the medication for
another DMTs [40].
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Hygienic measures such as energy conservation programs, specific rehabilitation interventions
physical (endurance, resistance, aerobic and combined training), aquatic therapy, cooling
therapies, Tai chi, stretching, mindfulness-based interventions, yoga, acupuncture, progressive
muscle relaxation and sleep hygiene advice (dependent on the nature of the sleep disorder) are
more effective than pharmacological interventions [41].
Adequate treatment of co-morbid conditions such as diabetes mellitus, congestive heart fail-
ure, obesity, sleep apnea and other sleep disorders, depression and anxiety with pharmacolog-
ical, psychological, behavioral and educational interventions is recommended [40, 41].
Pharmacological interventions for fatigue that are effective for reducing fatigue in patients
with MS include amantadine, pemoline, prokarin (1 pilot study, side effects not reported),
modafinil and pemoline combined with aspirin are efficacious for reducing fatigue in patients
with multiple sclerosis. Carnitine has a discreet effectiveness. In general, the risk benefit of the
drugs used for fatigue makes their recommendation be evaluated in each patient, highlighting
them to the amantadine [37, 41]. Aminopyridines and coenzyme Q10 have an effect on fatigue
by improving nerve conduction.
Nowadays, non-invasive brain stimulation (NIBS) techniques are gaining interest in the treat-
ment of MS fatigue [37].
Promotion of health behaviors such as quitting smoking, physical activity (a high level of
physical activity was borderline significantly associated with a decrease in co-morbidity) [42]
and healthy eating may prevent some co-morbidities which were slow to show improvement
in fatigue after the intervention, but they are effective [36].
3.2. Cognition
Cognitive impairment is a frequent feature of MS affecting up to 65% of patients [43] at both
the earlier and later stages of the disease [44] and it tends to worsen over time [45].
MS negatively affects several aspects of cognitive functions, including attention, information
processing [46], learning and memory, executive function and visuospatial abilities [47], hav-
ing an important impact on quality of life [48], employment status [49], daily functioning,
independence [50] and participation in social activities [51, 52].
Several factors have a negative influence on cognition in MS patients, such as depression [53],
fatigue and sleep disturbances. Proper sleep is important for memory consolidation [54], and
sleep deprivation has been related to impaired functioning in various cognitive domains [55].
Sleep disturbance causes a decrease in sustained attention [56], interferes with information
processing and executive functioning [52]. Sleep disturbed patients reported higher levels of
subjective cognitive problems compared to patients with normal sleep [52].
OSA and sleep disturbance are significantly associated with diminished visual memory, verbal
memory, executive function (as reflected by response inhibition), attention, processing speed
and working memory [52].
Excessive daytime sleepiness can lead to poor attention, poor memory, mood disturbances and
increased risk of accidents [29].
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In subjects with insomnia, a functional magnetic resonance imaging (fMRI) showed
hypoactivation of the medial and inferior prefrontal areas during a cognitive task, in relation
to the control subjects, which returned to normal values after treatment. Insomnia or super-
ficial sleep produces less activation of the hippocampus and less connectivity is observed in
the thalamus than in the control subjects. Damage to the hippocampus and thalamus (e.g.,
lesions and atrophy) in MS is associated with worse cognition. In controls, both regions may
be related to sleep and cognition [52].
MS patients performed worse on all cognitive tests compared to controls. MS patients had less
normalized gray matter (GM) volume, normalized white matter (WM) volume, hippocampal
volume and thalamic volume. The hippocampus and thalamus showed increased functional
connectivity (FC) in patients compared to controls, but lower FC was observed in patients with
sleep disturbances (32%) [52].
3.2.1. Diagnostic approach
Neuropsychological manifestations can even be detected in patients during early stages of the
disease. The Brief Repeatable Battery-Neuropsychology (BRB-N) [57] test was developed as a
short and sensitive test to identify disturbances of cognitive domains in MS patients. The BRB-
N has become the most widely used neuropsychological battery for MS, [58] and it is now
being applied in clinical trials to monitor cognitive changes.
Different cognitive impairment criteria have been used: <1.0 SD, <1.5 SD and <2.0 SD in one,
two or three subtests of the battery, respectively [59, 60].
3.2.2. Management
Strategies to optimize sleep could improve cognitive function in patients with MS.
In the case of insomnia, relaxation techniques such as autogenic training or progressive muscle
relaxation can help the patient fall asleep earlier and have a longer sleep. But they do not
improve sleep, so it has no sleep recovery effect. Behavioral therapies can improve sleep, but
not prolong it. A combination of relaxation techniques and behavior therapy could be the most
appropriate therapy for certain sleep disorders.
The general strategies for insomnia treatment include aspects of sleep hygiene such as exten-
sions of night time in bed and frequent naps during the day. Pharmacological treatment is
usually administered with stimulants such as amphetamines, methylphenidates, pemoline and
modafinil [61].
As regards sleep hygiene, it is often necessary to make some lifestyle changes such as dinner
should not be too late, nor too spicy or copious, maintain a regular sleep schedule, do not spend
too much time in bed other than bedtime, do not drink caffeinated beverages such as coffee,
black tea or cola, or caffeine medications, 4–6 hours before bedtime, do not smoke before going
to bed or during the night, try to get enough rest and darken the bedroom, ventilate the
bedroom, the temperature should not exceed 18, do not do any physically demanding sport
immediately before sleep because otherwise it will stimulate too much circulation, do not drink
alcohol before going to bed or avoid sleeping too much during the day.
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Patients with fatigue should organize daily routine and workloads. The physician also needs
to improve the efficiency of information processing and working memory in these patients
with fatigue [40].
Anxiety, depression, difficulty in sleeping and fatigue may have an impact on cognitive
problems. If a person with MS experiences these symptoms and has problems with memory
and cognition, they need to be provided with assessment and treatment (occupational thera-
pist and neuropsychologist).
The concept of mental toughness (MT) has recently been recognized for its psychological
importance not just in coping with stress but also for its association with increased physical
activity (PA), and for its impact on both stress and objective sleep quality. MT consists of four
key factors such as control (of own life and emotions), commitment, challenge and confidence
(in own abilities and in other people); thus covering a range of cognitive-emotional processes
closely involved in coping with stress, emotions, unexpected events and social setting [62].
3.3. Depression
Patients who suffer from problematic sleep and/or fatigue (with or without anxiety) may be
more likely to experience higher depressive symptoms [63].
Depression is a mental illness that causes feelings of sadness and loss of hope, changes in
sleeping and eating habits, loss of interest in your usual activities and pains that have no
physical explanation.
3.3.1. Diagnostic approach
A trans-diagnostic approach to symptoms may be more effective than targeting each symptom
separately, such as depression treatment or pain treatment alone. Trans-diagnostic models
explain how multiple co-morbid symptoms or disorders develop rather than create disorder
or symptom specific models [63].
3.3.2. Management
A trans-diagnostic treatment is an intervention that targets a range of diagnoses or problems
through the use of treatment strategies targeting psychological processes that are common across
disorders. It may be useful to consider all five factors such as depression, pain, anxiety, sleep and
fatigue in designing a treatment plan. Treatments for the constellation of biopsychosocial con-
cerns affecting many people living with MS.
The beneficial effects on depression of CBT targeting insomnia highlight a need for a compre-
hensive assessment of multiple concerns such as depression, anxiety, sleep problems or fatigue
when treating people with MS who report higher levels of pain [63].
3.4. Trigger for an acute multiple sclerosis exacerbation
The mechanism by which sleep disorders trigger an acute MS relapse might be multi-factorial.
Normal sleeping plays an important role in maintaining the normal function of the immune
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system. Various studies have shown that sleep disorders are associated with elevated serum
levels of pro-inflammatory cytokines and markers of oxidative stress [15].
The circadian regulation of cytokine output produces a daily rhythm in the inflammatory
profile, with a pro-inflammatory state occurring at night. Disrupted sleep can interfere with
this pattern leading to prolonged periods of inflammation throughout the day, thereby exacer-
bating symptoms. Furthermore, the circadian rhythmicity of key components of the immune
system has been shown to be dysregulated in MS patients [64].
The central circadian pacemaker, located in the hypothalamic suprachiasmatic nuclei, is
responsible for regulating the timing and expression of various circadian rhythms [65].
Sleep dysfunction and disruption in the circadian system alter the synchrony between these
transcriptional and translational feedback loops, resulting in increased cellular permeability,
which is thought to be an important underlying mechanism for initiating the inflammatory
cascades causing a disease flare. In addition, the presence of pro-inflammatory cytokines has
been proven to suppress the activity of circadian genes [65].
Melatonin is produced by the pineal gland that regulates circadian and seasonal rhythms.
Secretion of melatonin is suppressed during daylight and enhanced during the night, promotes
sleep by reducing sleep latency, decreasing wake time and increasing overall sleep quality [65].
Melatonin promotes anti-inflammatory states: it inhibits nitric oxide production, nuclear fac-
tor-κB activation and tumor necrosis factor- α, it reduces COX-2 expression and matrix
metalloproteinase activity (modulating apoptosis) [65].
Circadian sleep disorders are common in MS patients and could be linked to a disruption in
melatonin production, which is important in sleep-wake cycle regulation. Melatonin helps
dampen the overactive immune system and low levels are associated with relapse [64].
According to studies on an animal model, sleep deprivation is associated with an accelerated
autoantibody production rate and increases oxidative stress (toxic effect on oligodendrocytes
causing oligodendrocyte death and myelin damage). Chronic sleep deprivation breaks down
blood-brain barrier (BBB) thereby increasing permeability [15].
Sleep disorders also result in an elevated serum concentration of interleukin-6 (IL-6), which
further activates polyclonal B cells and triggers an autoimmune reaction. The serum concen-
tration of IL-6 is significantly associated with the number of relapses in female patients with
relapsing-remitting multiple sclerosis (RRMS) [15]. In the study of Sahraian et al. [15], the
group in relapse had worse scores of global PSIQI for the previous month than remission
group (87.5% were poor quality sleepers). Age, gender, EDSS and disease duration did not
associate with sleep quality in either group.
4. Co-morbidity condition
Co-morbidities have been shown to affect MS progression, time to initiation of the disease-
modifying therapy (DMT), as well as treatment compliance, which may be related to the
increased mortality of these patients as compared to the general population.
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Co-morbidities can negatively impact sleep in MS patients, which can, in turn, lead to a
worsening of symptoms, especially fatigue and pain.
Patients with sleep disorders are at risk of co-occurrence of other problems like vascular
diseases, obesity and diabetes that would threaten the health of patients in the long term [17].
Circadian disruptions occur in shift workers and appear to contribute to hypertension, diabetes,
breast cancer, lung cancer and elevated prostate-specific antigen. Shift work entails changes in diet,
exercise and tobacco use, which can confound circadian rhythm and sleep disturbance studies [65].
4.1. Narcolepsy
Narcolepsy is classified as a chronic sleep disorder associated with sleep attacks and other
features attributed to abnormalities of rapid eye movement sleep, such as hypnagogic/hypno-
pompic hallucinations, cataplexy, sleep paralysis and disrupted nocturnal sleep. The usual PSG
features include a mean sleep latency of less than or equal to 8 minutes and two or more sleep
onset rapid eye movement periods [6]. There is a high variability in the prevalence across different
geographic areas, which is thought to be related to differences between the populations and
current study methods [10].
Narcolepsy is estimated to affect 0.02–0.05% of the general population, the overall prevalence
of narcolepsy among persons with MS is unknown [6, 10].
There are two subtypes of primary narcolepsy which are described below.
Narcolepsy type 1(immune-mediated loss of hypocretin-secreting cells in the lateral hypothal-
amus) [6, 10] is characterized by the presence of cataplexy (a reliable clinical marker for
hypocretin deficiency) and hypocretin deficiency in CSF (<110 pg./dl).
Narcolepsy type 2: normal hypocretin levels [6, 10].
The secondary causes of narcolepsy show that MS is the fourth most common cause of
narcolepsy after inherited disorders, CNS tumors and brain injury, and it has been found that
12% of the cases of secondary narcolepsy were due to MS [6, 10, 66].
In terms of genetics, 95% of narcoleptic patients and 50–60% of MS patients are positive for
DR2 haplotype. The human leukocyte antigen (HLA) DQB1*0602, a known genetic risk factor
for narcolepsy, also influences the presence and severity of MS. Therefore, both diseases are
closely related to the same genes of the human leukocyte antigen (HLA) system, which is the
basis for labeling for most autoimmune diseases. This relationship suggests that similar auto-
immune factors may be at work in the development of each disorder and might be partially
responsible for symptoms of fatigue and sleepiness [6, 10, 67].
The aforementioned findings merit further attention given the potential impact of sleep disor-
ders on the health and quality of life of MS patients [10].
4.1.1. Diagnostic approach
A diagnosis of narcolepsy requires PSG and CSF hypocretin assays (only performed at a few
academic institutions).
Sleep Disorders in Multiple Sclerosis
http://dx.doi.org/10.5772/intechopen.72831
183
Narcolepsy cannot be established in the presence of concomitant OSA, insufficient sleep, shift
work or another circadian sleep disorder [10].
In such cases, adequate treatment of concomitant sleep disorders must be confirmed prior to
the multiple sleep latency testing.
The usual PSG features include a mean sleep latency of less than or equal to 8 minutes and two
or more sleep onset rapid eye movement periods [6].
It is necessary to perform MRI studies to rule out secondary causes of narcolepsy [6].
4.1.2. Management
Patients with suspected narcolepsy are usually referred for diagnosis and management by
sleep specialists: wake-promoting agents or stimulants may be used to increase wakefulness
and vigilance.
Sodium oxybate (an endogenous metabolite of gamma-aminobutyric acid (GABA) may be
used in selected cases.
REM-suppressing antidepressants may be useful for cataplexy and sleep paralysis.
In cases of secondary narcolepsy when new hypothalamic lesions are identified, a trial of high-
dose steroids should be considered [6].
4.2. Overweight and obesity
Being overweight is having more body fat than is optimally healthy. The degree to which a
person is overweight is generally described by the body mass index (BMI). Overweight is
defined as a BMI above or equal to 25 and below 30.
Obesity is defined as a BMI over 30. The prevalence of overweight and obesity in patients with
multiple sclerosis ranges from 19 to 55%. These differences are due to the distinct prevalence in
the general population, differences in geographic origin, population type (military veterans or
hospital users) and/or age group. It is notable that the American population has the highest
numbers of obesity. Besides which, it is worth mentioning the different methodology used,
including overweight with obesity in some studies [42, 68].
Spanish data (NARCOMS study) have shown that overweight people with MS had lower
general and mental health scores compared to those with normal weight and found no differ-
ences in other quality of life scales of the SF-36 [69].
Depression levels were higher in the overweight versus normal weight MS Spanish patients.
This finding is due to pathophysiological mechanisms common to both depression and obe-
sity, given that chronic low-grade pro-inflammatory states can generate various abnormalities
in different neural networks [69].
BMI was significantly related to levels of disability, with obese participants 1.4 times more
likely to have moderate/severe disability while controlling for age, gender, time since diag-
nosis and number of co-morbidities. As the BMI increases, the number of co-morbidities
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increases with higher odds for disability and prior relapse and lower health-related quality
of life [42].
Central obesity, as defined by increased waist circumference, absolute waist circumference
>102 cm in men and >88 cm in women or waist-hip ratio (the circumference of the waist
divided by that of the hips) of >0.9 for men and >0.85 for women, is often indicative of
metabolic syndrome, and is suggested to be a more potent risk factor (cardiovascular disease,
Alzheimer’s diseases and type 2 diabetes) than body mass index alone.
4.2.1. Diagnostic approach
Weight, height, BMI = weight (kg)/height (m2), waist circumference and waist-hip ratio.
4.2.2. Management
Patients who are overweight and obese are usually referred for diagnosis and management by
a multidisciplinary team such as specialist nutritionist, physiotherapists, surgeons and neuro-
psychologists.
Gradual weight loss and gentle physical exercise and stretching are recommended. Small
meals and small amounts of food, low in animal fats and fresh fruits. Bariatric surgery may
be necessary in severe cases of obesity.
Co-morbidities have been shown to be associated with increased hospitalization, rate of pro-
gression to disability, decreased quality of life and increased mortality risk which is why they
have to be properly treated [42].
Adverse health behavior including being overweight and obese, smoking and sedentary
behavior are common in people with MS [42]. These behaviors can be modified and may
significantly change the level of health. Health professionals should be focused on achieving
these behavioral changes in patients with MS.
5. Influence of the treatment of multiple sclerosis in sleep
The therapeutic approach to multiple sclerosis involves pharmacological, rehabilitative, psy-
chological, lifestyle modifying interventions, etc. These can be used independently or coordi-
nated with each other with a holistic view. This approach involves changes in the structure of
sleep, which are not always beneficial.
5.1. Treatment of relapses
Therapeutic options to treat MS relapses include oral glucocorticosteroids [70, 71] or their
intravenous administration at a high dose as first line and therapeutic plasma exchange (TPE)
and intravenous immunoglobulin (IVIG) as second line treatments in glucocorticosteroids
unresponsive patients [72], corticotrophin injection and Acthar [73].
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The action mechanisms of glucocorticosteroids in the immune system are pleiotropic, induced
apoptosis of peripheral blood leucocytes and down-regulation of T-cell activity delayed for
7–10 days after a 5-day course of administration [72].
TPE is the removal of circulating antibodies, cytokines, immune complexes and complemen-
tary factors, all of which are assumed to be involved in immune-mediated neuroinflammation.
IVIG reduces or prevents the activation of inflammatory cells and alters antibody responses.
Optimal treatment of relapses increases the chance of limiting or avoiding residual deficits
which have been related to the progression of disability in MS [72].
Sleep disturbance (insomnia) might be one of the side effects of corticosteroid therapy during
an acute exacerbation in MS. Benzodiazepines are useful during these periods [74].
5.2. Disease-modifying therapies
Interferons are DMTs that produce major alterations of sleep, mainly by the flulike reaction,
fever, headache, alteration of the mood and fatigue. It is imperative to treat these effects to
improve the patient’s quality of life including finding what time is best to administer the
treatment. The monoclonal antibody Natalizumab could reduce fatigue [37].
5.3. Symptomatic treatment
Specific treatment of symptoms of MS manifestations occasionally interferes with sleep quality,
leading to insomnia or drowsiness. The treatments the patient is receiving need to be reviewed
in the event of any sleep disturbance.
Selective serotonin reuptake inhibitors, while helpful for depressive symptoms, may worsen
insomnia. Stimulants and wake-promoting agents, which are commonly used for fatigue, may
interfere with sleep initiation if taken during the late afternoon or early evening hours. Anti-
histamines, which are used as sleep aids by up to 25% of patients with MS, have the potential
to worsen RLS, and thereby worsen sleep-onset insomnia.
Patients suffering from fatigue symptoms are often treated with antidepressants due to the
strong association between depression and fatigue. Modafinil, amantadine and aminopyridine
are known as fatigue treatment options, although the physician must monitor the real effect on
sleep and adjust the administration schedules so as not to mask the effect on fatigue.
Medications used to alleviate MS-related symptoms, including over-the-counter medications,
also have the potential to interfere with sleep. Given the high frequency use of these medica-
tions in this population, the physician should carefully consider screening for these medica-
tions and assessing possible effects on sleep.
5.3.1. Management
The first approach includes reviewing the list of drugs being taken by the patient and adjusting
doses or suspending them if necessary to avoid interference with other situations of the
patient. In this respect, the multidisciplinary approach to the patient is important.
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6. Conclusions
Sleep disorders in patients with MS are frequently underdiagnosed. Clinicians caring for
patients with MS should routinely screen for sleep disturbances.
All the symptoms are related, many of them share the same pathophysiology where it is not
possible to identify the precipitating factor and the perpetuating factor. Sleep disturbances
increase the risk of mortality, co-morbidities (cardiac disease, obesity and diabetes) and can
contribute to the depression, pain, cognitive impairment and fatigue symptoms which are
disabling and worsen the prognosis of multiple sclerosis.
The therapeutic approach to sleep disorders in MS involves pharmacological, rehabilitative,
physical, psychological, educational and lifestyle modification interventions. These can be
used independently in combination, with combined therapies being more effective.
The list of drugs being taken by the patient should always be reviewed and doses should be
adjusted or suspended if necessary to avoid interference with sleeps disorders.
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